| |
Isentress Label Updated with 96 weeks Data
|
| |
| |
On June 29, 2010, the Isentress (raltegravir potassium) tablet label was updated with the Week 96 safety and efficacy results in treatment-naïve and treatment-experienced patients.
In the treatment-naïve trial 021, the proportion of subjects with HIV RNA < 50 copies/mL was 82% for the Isentress 400 mg twice daily regimen compared to 78% for the Efavirenz arm. The treatment difference and 95% CI was 3.8% (-2.8%, 10.4%).
In the treatment-experienced pooled analysis of trials 018 and 019, the proportion of subjects with HIV RNA < 50 copies/mL was 55% for the Isentress 400 mg twice daily + optimized background regimen compared to 27% for the optimized background regimen arm.
Section 6 of the label was updated to include the Week 96 safety results.
The complete revised label will be posted soon to the FDA website at Drugs@FDA. Be sure to check for 6/29/2010 update.
Richard Klein
Office of Special Health Issues
Food and Drug Administration
Kimberly Struble
Division of Antiviral Drug Products
Food and Drug Administration
| |
| |
| |
|
|
|
